417 related articles for article (PubMed ID: 29510685)
21. Management of recurrent hepatitis C after liver transplantation.
Teixeira R; Papatheodoridis GV; Burroughs AK
J Viral Hepat; 2001 May; 8(3):159-68. PubMed ID: 11380792
[TBL] [Abstract][Full Text] [Related]
22. Clearance of hepatitis C virus after living-donor liver transplantation in spite of residual viremia on end date of interferon therapy before transplantation.
Ichikawa T; Nakao K; Hamasaki K; Honda T; Shibata H; Akahoshi M; Eguchi S; Takatsuki M; Kanematsu T; Eguchi K
World J Gastroenterol; 2007 Aug; 13(30):4149-51. PubMed ID: 17696240
[TBL] [Abstract][Full Text] [Related]
23. Early and extended therapy for recurrent hepatitis C after liver transplantation.
García-Pajares F; Almohalla C; Lorenzo Pelayo S; Ruiz Zorrilla R; Pinto P; Ramos C; Sanchez Antolin G; Paton AC
Transplant Proc; 2012; 44(6):1571-3. PubMed ID: 22841217
[TBL] [Abstract][Full Text] [Related]
24. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.
Rodriguez-Luna H; Khatib A; Sharma P; De Petris G; Williams JW; Ortiz J; Hansen K; Mulligan D; Moss A; Douglas DD; Balan V; Rakela J; Vargas HE
Transplantation; 2004 Jan; 77(2):190-4. PubMed ID: 14742979
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C virus and liver transplantation: where do we stand?
Burra P; De Martin E; Zanetto A; Senzolo M; Russo FP; Zanus G; Fagiuoli S
Transpl Int; 2016 Feb; 29(2):135-52. PubMed ID: 26199060
[TBL] [Abstract][Full Text] [Related]
26. [A clinicopathologic study on complications of orthotopic liver transplantation in 54 patients with chronic hepatitis B virus infection].
Pei F; Zheng J; Du J; Zhong HH; Yang JP
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):408-14. PubMed ID: 18677390
[TBL] [Abstract][Full Text] [Related]
27. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients.
Mukherjee S; Lyden E; McCashland TM; Schafer DF
J Gastroenterol Hepatol; 2005 Feb; 20(2):198-203. PubMed ID: 15683421
[TBL] [Abstract][Full Text] [Related]
28. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant.
Kwo PY; Ghabril M; Lacerda MA; Joseph Tector A; Fridell JA; Vianna R
Clin Transplant; 2014 Jun; 28(6):722-7. PubMed ID: 24708229
[TBL] [Abstract][Full Text] [Related]
29. [HCV reinfection after liver transplantation for HCV cirrhosis].
Pasquale G; Iannicelli P; Martini S; Mogavero AR; Caprio N
Infez Med; 2005 Dec; 13(4):215-28. PubMed ID: 16388277
[TBL] [Abstract][Full Text] [Related]
30. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
31. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
32. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
Bizollon T; Palazzo U; Ducerf C; Chevallier M; Elliott M; Baulieux J; Pouyet M; Trepo C
Hepatology; 1997 Aug; 26(2):500-4. PubMed ID: 9252166
[TBL] [Abstract][Full Text] [Related]
33. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
[TBL] [Abstract][Full Text] [Related]
34. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
35. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
36. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
37. Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
Motoyama H; Tamori A; Kubo S; Uchida-Kobayashi S; Takemura S; Tanaka S; Ohfuji S; Teranishi Y; Kozuka R; Kawamura E; Hagihara A; Morikawa H; Enomoto M; Murakami Y; Kawada N
PLoS One; 2018; 13(3):e0194163. PubMed ID: 29534101
[TBL] [Abstract][Full Text] [Related]
38. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
Beste LA; Green PK; Berry K; Kogut MJ; Allison SK; Ioannou GN
J Hepatol; 2017 Jul; 67(1):32-39. PubMed ID: 28267622
[TBL] [Abstract][Full Text] [Related]
40. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
Donato MF; Monico S; Malinverno F; Aghemo A; Maggioni M; Reggiani P; Colombo M
Liver Int; 2015 Jan; 35(1):1-4. PubMed ID: 25074044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
